Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Myriad Genetics (MYGN) Equity Average (2016 - 2026)

Myriad Genetics has reported Equity Average over the past 15 years, most recently at $370.4 million for Q4 2025.

  • Quarterly Equity Average fell 48.3% to $370.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $370.4 million through Dec 2025, down 48.3% year-over-year, with the annual reading at $534.6 million for FY2025, 27.97% down from the prior year.
  • Equity Average was $370.4 million for Q4 2025 at Myriad Genetics, down from $380.4 million in the prior quarter.
  • Over five years, Equity Average peaked at $968.2 million in Q4 2021 and troughed at $370.4 million in Q4 2025.
  • The 5-year median for Equity Average is $778.4 million (2023), against an average of $773.7 million.
  • Year-over-year, Equity Average increased 9.21% in 2022 and then plummeted 48.32% in 2025.
  • A 5-year view of Equity Average shows it stood at $968.2 million in 2021, then decreased by 6.92% to $901.2 million in 2022, then decreased by 18.63% to $733.3 million in 2023, then decreased by 2.3% to $716.4 million in 2024, then plummeted by 48.3% to $370.4 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Equity Average are $370.4 million (Q4 2025), $380.4 million (Q3 2025), and $546.5 million (Q2 2025).